Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study Clinical trials frequently include multiple end points that ...

Globally, an estimated 133,818 new patients of serous cancer, 35,712 new patients of mucinous cancer, 29,319 new patients of endometrioid cancer, and 17,894 new patients of clear cell cancer were ...